One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Epilepsy syndromes: an essential piece of the puzzle
doi : 10.1016/S1474-4422(22)00226-5
Volume 21, Issue 7, July 2022, Page 577
A new option for patients with treatment-resistant migraine
RaffaeleOrnelloaSimonaSaccoa
Natalizumab for multiple sclerosis: the dilemma of NOVA
KerstinHellwiga
Treatment decision making in acute subdural haematoma
Paul MBrennana
Huntington's disease: disappointments and new beginnings
CarstenSafta
Major advances in neuromuscular disorders in the past two decades
Renske IWadmanaWouter vanRheenenaW Ludovan der PolaLeonard Hvan den Berga
Imaging of the carotid artery
Nicholas REvansabdJames H FRuddcElizabeth AWarburtonb
Imaging of the carotid artery – Authors' reply
Martin MBrownaLeo HBonatib
The Mobile Toolbox for monitoring cognitive function
Richard CGershonaMarti JSliwinskibLaraMangravitecJonathan WKingdAaron JKaataMichael WWeinereDorene MRentzfgh
Tanuja Chitnis: on role models, family, and multiple sclerosis
AdrianBurton
Access to investigational drugs for patients with amyotrophic lateral sclerosis in the USA
Holly FernandezLynchSandraMorrisJinsy AAndrews
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
ProfMessoudAshinaMDaMichelLanteri-MinetMDbcPatriciaPozo-RosichPhDdeAndersEttrupPhDfCecilie LaurbergChristoffersenMScfMette KrogJosiassenPhDfRavinderPhulPhDfBjørnSperlingMDf
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
John FFoleyMDaProfGillesDeferMDbLana ZhovtisRyersonMDcProfJeffrey ACohenMDdProfDouglas LArnoldMDefProfHelmutButzkuevenPhDgProfGaryCutterPhDhProfGavinGiovannoniMDijProfJoepKillesteinMDkProfHeinzWiendlMDlKarenSmirnakisMDmShanXiaoPhDmGeorgeKongPhDmRobertKuheljPhDnNolanCampbellPhDm
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study
Thomas Avan EssenMDaProfHester FLingsmaPhDbDanaPisicăbcRanjit DSinghMDaVictorVoloviciMDbcHugo Fden BoogertMDeAlexanderYounsiMDfLianne DPeppelMScdMajanka HHeijenbrok-KalPhDdProfGerard MRibbersMDdRobertWalchenbachMDaProfDavid KMenonMDgProfPeterHutchinsonMDhiProfBartDepreitereMDjProfEwout WSteyerbergPhDbkProfAndrew I RMaasMDlGodard C Wde RuiterMDaProfWilco CPeulMDa
A biological classification of Huntington's disease: the Integrated Staging System
ProfSarah JTabriziPhDa*ScottSchobelMDb*Emily CGantmanPhDcAlexandraMansbachJDeBethBorowskyPhDfPavlinaKonstantinovaPhDgTiago AMestrePhDhJenniferPanagouliasRACiProfChristopher ARossMDjkMauriceZaudererPhDlAriana PMullinPhDiKlausRomeroMDmSudhirSivakumaranPhDmEmily CTurnerPhDmProfJeffrey DLongPhDnProfCristinaSampaioMDcdHuntington's Disease Regulatory Science Consortium (HD-RSC)â€
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities
ProfSarah JTabriziPhDaCarlosEstevez-FragaMDaProfWilleke M Cvan Roon-MomPhDbMichael DFloweraRachael IScahillPhDaProfEdward JWildPhDaIgnacioMuñoz-SanjuanPhDcProfCristinaSampaioPhDcdProfAnne ERosserPhDeProfBlair RLeavittMDCMf
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials
Carl MZipserMDaJacquelyn JCraggPhDbcProfJames DGuestMDdProfMichael GFehlingsMDeProfCatherine RJutzelerPhDfProfAileen JAndersonPhDgProfArminCurtMDa
